UBE2G1

Summary

UBE2G1 (ubiquitin conjugating enzyme E2 G1, HGNC:12482) is a protein-coding gene on chromosome 17p13.2, encoding Ubiquitin-conjugating enzyme E2 G1 (P62253). Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins.

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family and catalyzes the covalent attachment of ubiquitin to other proteins. The protein may be involved in degradation of muscle-specific proteins.

Source: NCBI Gene 7326 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 11 total
• MANE Select transcript: NM_003342

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12482
Approved symbol	UBE2G1
Name	ubiquitin conjugating enzyme E2 G1
Location	17p13.2
Locus type	gene with protein product
Status	Approved
Aliases	UBC7
Ensembl gene	ENSG00000132388
Ensembl biotype	protein_coding
OMIM	601569
Entrez	7326

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 10 protein_coding, 2 nonsense_mediated_decay

ENST00000396981, ENST00000571953, ENST00000571980, ENST00000572484, ENST00000574059, ENST00000574633, ENST00000877982, ENST00000877983, ENST00000877984, ENST00000877985, ENST00000923588, ENST00000957659

RefSeq mRNA: 1 — MANE Select: NM_003342 NM_003342

CCDS: CCDS32532

Canonical transcript exons

ENST00000396981 — 6 exons

Exon	Start	End
ENSE00001254536	4269259	4272516
ENSE00002657238	4366271	4366675
ENSE00003469502	4282798	4282921
ENSE00003517157	4307021	4307123
ENSE00003652848	4289230	4289408
ENSE00003659468	4296717	4296814

Expression profiles

Bgee: expression breadth ubiquitous, 294 present calls, max score 99.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 47.4622 / max 267.7466, expressed in 1825 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163908	23.4252	1819
163912	21.0959	1810
163910	1.6865	1141
163909	0.6815	423
163911	0.4619	210
163907	0.0908	31
163906	0.0204	4

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	99.60	gold quality
secondary oocyte	CL:0000655	99.09	gold quality
biceps brachii	UBERON:0001507	98.72	gold quality
vastus lateralis	UBERON:0001379	98.71	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.69	gold quality
quadriceps femoris	UBERON:0001377	98.58	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.40	gold quality
skeletal muscle tissue	UBERON:0001134	98.37	gold quality
oocyte	CL:0000023	98.07	gold quality
esophagus squamous epithelium	UBERON:0006920	98.04	gold quality
gluteal muscle	UBERON:0002000	97.99	gold quality
deltoid	UBERON:0001476	97.98	gold quality
epithelium of esophagus	UBERON:0001976	97.95	gold quality
male germ cell	CL:0000015	97.89	gold quality
muscle organ	UBERON:0001630	97.64	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.61	gold quality
tibialis anterior	UBERON:0001385	97.51	gold quality
gastrocnemius	UBERON:0001388	97.33	gold quality
body of tongue	UBERON:0011876	97.27	gold quality
muscle of leg	UBERON:0001383	97.25	gold quality
heart right ventricle	UBERON:0002080	97.03	gold quality
triceps brachii	UBERON:0001509	96.91	gold quality
diaphragm	UBERON:0001103	96.83	gold quality
muscle tissue	UBERON:0002385	96.81	gold quality
tongue	UBERON:0001723	96.40	gold quality
pharyngeal mucosa	UBERON:0000355	96.36	gold quality
oral cavity	UBERON:0000167	96.35	gold quality
squamous epithelium	UBERON:0006914	96.32	gold quality
tongue squamous epithelium	UBERON:0006919	96.31	gold quality
left ventricle myocardium	UBERON:0006566	95.70	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-3929	yes	1088.38
E-MTAB-7606	no	219.30
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT3

miRNA regulators (miRDB)

241 targeting UBE2G1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6759-5P	99.99	66.54	785
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-1250-3P	99.96	70.04	4038

Literature-anchored findings (GeneRIF, showing 5)

• In endoplasmic reticulum, involved in the degradation of type 2 iodothyronine selenodeiodinase (PMID:12933904)
• study reports that UBCH8 and UBE2G1 and UBE2G2 cooperate with CRL4Cdt2 in promoting the polyubiquitylation and subsequent degradation of p21 and Cdt1, respectively (PMID:21628527)
• ubiquitin binding by the acidic loops of Ube2g1 and Ube2r1 enzymes distinguishes their Lys-48-ubiquitylation activities (PMID:25471371)
• the ubiquitin-conjugating enzymes UBE2G1 and UBE2D3 cooperatively promote the K48-linked polyubiquitination of CRL4(CRBN) neomorphic substrates (PMID:30234487)
• UBE2R2 alone had negligible ubiquitylation activity at physiological concentrations and the ablation of UBE2R1/2 had no effect on the stability of SCF substrates in cells. A genome-wide CRISPR screen revealed that an additional E2 enzyme, UBE2G1, buffers against the loss of UBE2R1/2. (PMID:31868589)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	ube2g1a	ENSDARG00000015292
mus_musculus	Ube2g1	ENSMUSG00000020794
rattus_norvegicus	Ube2g1	ENSRNOG00000010041
rattus_norvegicus	Ube2g1l1	ENSRNOG00000066375
drosophila_melanogaster	CG40045	FBGN0058045
drosophila_melanogaster	Ubc87F	FBGN0267383
caenorhabditis_elegans		WBGENE00006704

Paralogs (24): UBE2T (ENSG00000077152), UBE2A (ENSG00000077721), UBE2K (ENSG00000078140), CDC34 (ENSG00000099804), UBE2I (ENSG00000103275), UBE2W (ENSG00000104343), UBE2R2 (ENSG00000107341), UBE2S (ENSG00000108106), UBE2B (ENSG00000119048), UBE2Z (ENSG00000159202), UBE2J2 (ENSG00000160087), AKTIP (ENSG00000166971), UBE2V2 (ENSG00000169139), UBE2C (ENSG00000175063), UBE2O (ENSG00000175931), UBE2U (ENSG00000177414), UBE2N (ENSG00000177889), UBE2F (ENSG00000184182), UBE2G2 (ENSG00000184787), UBE2H (ENSG00000186591), UBE2J1 (ENSG00000198833), PEDS1 (ENSG00000240849), UBE2V1 (ENSG00000244687), UBE2NL (ENSG00000276380)

Protein

Protein identifiers

Ubiquitin-conjugating enzyme E2 G1 — P62253 (reviewed: P62253)

Alternative names: E2 ubiquitin-conjugating enzyme G1, E217K, UBC7, Ubiquitin carrier protein G1, Ubiquitin-protein ligase G1

All UniProt accessions (5): P62253, I3L0Q0, I3L2H7, I3L2Q4, K7EPR7

UniProt curated annotations — full annotation on UniProt →

Function. Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes ‘Lys-48’-, as well as ‘Lys-63’-linked polyubiquitination. May be involved in degradation of muscle-specific proteins. Mediates polyubiquitination of CYP3A4.

Tissue specificity. Widely expressed, mainly in skeletal muscle.

Post-translational modifications. Autoubiquitinated in vitro.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the ubiquitin-conjugating enzyme family.

RefSeq proteins (1): NP_003333* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000608	UBC	Domain
IPR016135	UBQ-conjugating_enzyme/RWD	Homologous_superfamily
IPR023313	UBQ-conjugating_AS	Active_site
IPR050113	Ub_conjugating_enzyme-E2-like	Family

Pfam: PF00179

Enzyme classification (BRENDA):

• EC 2.3.2.23 — E2 ubiquitin-conjugating enzyme (BRENDA: 20 organisms, 93 substrates, 28 inhibitors, 12 Km, 8 kcat entries)
• EC 2.3.2.24 — (E3-independent) E2 ubiquitin-conjugating enzyme (BRENDA: 5 organisms, 56 substrates, 7 inhibitors, 6 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
[UBIQUITIN-CARRIER-PROTEIN UBC2B]-L-CYSTEINE	0.0001	5
[UBE2W]-S-UBIQUITINYL-L-CYSTEINE	0.2203–0.3014	2
[HISTONE H2A]-L-LYSINE	0.0008–0.0028	2
[HISTONE H2B]-L-LYSINE	0.0015–0.012	2
S-UBIQUITINYL-[E1 UBIQUITIN-ACTIVATING ENZYME]-L	1	1
[UBIQUITIN CARRIER PROTEIN UBC4]-L-CYSTEINE	0.0019	1
[CYTOCHROME C]-L-LYSINE	0.125	1
[HISTONE H3]-L-LYSINE	0.0013	1

UniProt features (20 total): strand 5, helix 5, turn 3, chain 2, modified residue 2, initiator methionine 1, domain 1, active site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2AWF	X-RAY DIFFRACTION	2.1
6D68	X-RAY DIFFRACTION	2.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P62253-F1	94.20	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 90 (glycyl thioester intermediate)

Post-translational modifications (2): 1, 2

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8866652	Synthesis of active ubiquitin: roles of E1 and E2 enzymes
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation

MSigDB gene sets: 229 (showing top): BORCZUK_MALIGNANT_MESOTHELIOMA_UP, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, BROWNE_HCMV_INFECTION_8HR_UP, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, WONG_PROTEASOME_GENE_MODULE, AATGGAG_MIR136, PUJANA_CHEK2_PCC_NETWORK, GTGCCTT_MIR506, MODULE_120, FISCHER_G2_M_CELL_CYCLE, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, GENTILE_UV_HIGH_DOSE_DN

GO Biological Process (7): protein polyubiquitination (GO:0000209), ubiquitin-dependent protein catabolic process (GO:0006511), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), protein K63-linked ubiquitination (GO:0070534), protein K48-linked ubiquitination (GO:0070936), protein ubiquitination (GO:0016567), protein modification by small protein conjugation (GO:0032446)

GO Molecular Function (8): ubiquitin-protein transferase activity (GO:0004842), ATP binding (GO:0005524), ubiquitin protein ligase binding (GO:0031625), ubiquitin conjugating enzyme activity (GO:0061631), nucleotide binding (GO:0000166), protein binding (GO:0005515), transferase activity (GO:0016740), ubiquitin-like protein transferase activity (GO:0019787)

GO Cellular Component (2): cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Protein ubiquitination	1
Class I MHC mediated antigen processing & presentation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein ubiquitination	2
protein polyubiquitination	2
modification-dependent protein catabolic process	1
ubiquitin-dependent protein catabolic process	1
proteasomal protein catabolic process	1
protein modification by small protein conjugation	1
protein modification by small protein conjugation or removal	1
ubiquitin-like protein transferase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ubiquitin-like protein ligase binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein conjugating enzyme activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
aminoacyltransferase activity	1
catalytic activity, acting on a protein	1
cytoplasm	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

2984 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
UBE2G1	SGK3	Q96BR1	770
UBE2G1	ASIC1	P78348	743
UBE2G1	SYVN1	Q86TM6	665
UBE2G1	AMFR	P26442	637
UBE2G1	UBE2J2	Q8N2K1	616
UBE2G1	UBE2V2	Q15819	614
UBE2G1	CRBN	Q96SW2	560
UBE2G1	UBA1	P22314	546
UBE2G1	CUL2	Q13617	543
UBE2G1	UBE4B	O95155	524
UBE2G1	GINM1	Q9NU53	504
UBE2G1	SGK1	O00141	496
UBE2G1	UBE4A	Q14139	493
UBE2G1	UBE2Q1	Q7Z7E8	487
UBE2G1	FBXO9	Q9UK97	479

IntAct

22 interactions, top by confidence:

A	B	Type	Score
UBE2G1	CCK	psi-mi:“MI:0915”(physical association)	0.560
UBE2G1	GNB2	psi-mi:“MI:0915”(physical association)	0.560
LAMP2	UBE2G1	psi-mi:“MI:0915”(physical association)	0.560
UBE2G1	SH3GLB1	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	UBE2G1	psi-mi:“MI:0915”(physical association)	0.560
CUL1	Il1rl1	psi-mi:“MI:0220”(ubiquitination reaction)	0.440
UBE2G1	RBCK1	psi-mi:“MI:0915”(physical association)	0.370
Tmed10	NDUFS8	psi-mi:“MI:0914”(association)	0.350
UBA52	VCP	psi-mi:“MI:0914”(association)	0.350
IL36G	GOT1	psi-mi:“MI:0914”(association)	0.350
RNF144A	COL1A1	psi-mi:“MI:0914”(association)	0.350

BioGRID (69): UBE2G1 (Reconstituted Complex), UBE2G1 (Biochemical Activity), UBE2G1 (Affinity Capture-MS), UBE2G1 (Reconstituted Complex), UBE2G1 (Affinity Capture-MS), UBE2G1 (Reconstituted Complex), UBE2G1 (Affinity Capture-RNA), UBE2G1 (Co-fractionation), UBE2G1 (Reconstituted Complex), UBE2G1 (Affinity Capture-MS), UBE2G1 (Reconstituted Complex), UBE2G1 (Reconstituted Complex), UBE2G1 (Biochemical Activity), UBE2G1 (Affinity Capture-RNA), UBE2G1 (Reconstituted Complex)

ESM2 similar proteins: A3KN22, O74549, P0C8G3, P21734, P25869, P27949, P49427, P51965, P52482, P52491, P61081, P61082, P62253, P62254, P62255, Q08BH7, Q1RMW1, Q29503, Q3UWQ3, Q42540, Q42541, Q54TI6, Q55EY8, Q5M8Y2, Q5U203, Q5ZKX6, Q6C9W0, Q6CSW8, Q6DCZ9, Q6FVQ8, Q6IRC7, Q6NY82, Q6P8D9, Q6ZWZ2, Q712K3, Q75AF2, Q7ZY08, Q8CFI2, Q91W82, Q95017

Diamond homologs: A0A1B0GUS4, A5PJC4, A5PKP9, D3ZDK2, O13685, O14933, O74196, O74810, P0C8G3, P0C8G4, P0C8G5, P15731, P15732, P21734, P25867, P25869, P27949, P35128, P35129, P35131, P35132, P35133, P35134, P35135, P43102, P46595, P49427, P51668, P51965, P52482, P52483, P52485, P52487, P52490, P52492, P61077, P61078, P61079, P61080, P61088

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
“Ub:E1 (UBA1 substrate)”	“up-regulates activity”	UBE2G1	ubiquitination
“Ub:E1 (UBA6 substrate)”	“up-regulates activity”	UBE2G1	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1868 predictions. Top by Δscore:

Variant	Effect	Δscore
17:4282918:CTTT:C	acceptor_gain	1.0000
17:4282922:C:CC	acceptor_gain	1.0000
17:4289224:CCTTA:C	donor_loss	1.0000
17:4289225:CTTA:C	donor_loss	1.0000
17:4289226:TTAC:T	donor_loss	1.0000
17:4289227:TAC:T	donor_loss	1.0000
17:4289228:A:AC	donor_gain	1.0000
17:4289229:C:CC	donor_gain	1.0000
17:4289229:C:CT	donor_loss	1.0000
17:4289229:CCG:C	donor_gain	1.0000
17:4289370:CA:C	acceptor_gain	1.0000
17:4289371:A:AC	acceptor_gain	1.0000
17:4289371:A:C	acceptor_gain	1.0000
17:4289405:TCAA:T	acceptor_gain	1.0000
17:4289406:CAA:C	acceptor_gain	1.0000
17:4289406:CAAC:C	acceptor_gain	1.0000
17:4289409:C:CC	acceptor_gain	1.0000
17:4296815:C:CC	acceptor_gain	1.0000
17:4307012:TATAC:T	donor_loss	1.0000
17:4307013:ATACT:A	donor_loss	1.0000
17:4307014:TACTT:T	donor_loss	1.0000
17:4307015:ACTT:A	donor_loss	1.0000
17:4307016:CTTAC:C	donor_loss	1.0000
17:4307017:TT:T	donor_loss	1.0000
17:4307018:TACTA:T	donor_loss	1.0000
17:4307019:A:AC	donor_gain	1.0000
17:4307019:ACTAA:A	donor_loss	1.0000
17:4307020:C:CA	donor_gain	1.0000
17:4307020:C:G	donor_loss	1.0000
17:4307020:CT:C	donor_gain	1.0000

AlphaMissense

1119 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:4289234:G:T	A141D	1.000
17:4289287:A:C	S123R	1.000
17:4289287:A:T	S123R	1.000
17:4289289:T:G	S123R	1.000
17:4289323:C:A	W111C	1.000
17:4289323:C:G	W111C	1.000
17:4289325:A:G	W111R	1.000
17:4289325:A:T	W111R	1.000
17:4289375:A:G	L94P	1.000
17:4296788:A:G	L59P	1.000
17:4307058:A:G	W38R	1.000
17:4307058:A:T	W38R	1.000
17:4282878:A:T	V157D	0.999
17:4289246:G:T	A137D	0.999
17:4289249:G:T	P136H	0.999
17:4289273:A:G	L128P	0.999
17:4289280:A:G	S126P	0.999
17:4289285:A:T	V124D	0.999
17:4289297:A:T	I120N	0.999
17:4289321:A:G	L112P	0.999
17:4289324:C:G	W111S	0.999
17:4289327:C:G	R110P	0.999
17:4289328:G:T	R110S	0.999
17:4289341:T:A	E105D	0.999
17:4289341:T:G	E105D	0.999
17:4289342:T:A	E105V	0.999
17:4289358:C:G	D100H	0.999
17:4289371:A:C	H95Q	0.999
17:4289371:A:T	H95Q	0.999
17:4289373:G:C	H95D	0.999

dbSNP variants (sampled 300 via entrez): RS1000002842 (17:4360245 TA>T,TAA), RS1000014444 (17:4365449 A>G), RS1000091977 (17:4301095 A>G,T), RS1000117274 (17:4307728 C>A), RS1000143879 (17:4329062 G>A), RS1000159153 (17:4347390 T>C), RS1000184489 (17:4328825 G>A), RS1000203414 (17:4320552 G>A), RS1000238580 (17:4337415 G>A), RS1000247681 (17:4312837 A>T), RS1000278702 (17:4312651 G>A,C), RS1000303792 (17:4274396 A>G), RS1000318931 (17:4295768 A>T), RS1000321494 (17:4358003 GA>G,GAA), RS1000327883 (17:4331864 T>C)

Disease associations

OMIM: gene MIM:601569 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST004484_4	Plasma trimethylamine N-oxide levels	9.000000e-08
GCST004746_49	Small cell lung carcinoma	2.000000e-06
GCST010002_118	Refractive error	6.000000e-14
GCST010396_87	Gut microbiota (bacterial taxa, hurdle binary method)	9.000000e-07
GCST012298_8	Schizophrenia, bipolar disorder or major depressive disorder x sex interaction	5.000000e-06
GCST012309_3	Schizophrenia	2.000000e-06

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005691	plasma trimethylamine N-oxide measurement
EFO:0007874	gut microbiome measurement
EFO:0008343	sex interaction measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
bisphenol A	decreases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
beta-methylcholine	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
monomethylarsonous acid	increases expression	1
ICG 001	increases expression	1
jinfukang	decreases expression	1
Acetaminophen	increases expression	1
Atrazine	decreases expression	1
Cisplatin	decreases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Paraquat	increases expression	1
Potassium Dichromate	increases expression	1
Rotenone	increases expression	1
Sarin	decreases expression	1
Dihydrotestosterone	increases expression	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1
Valproic Acid	affects expression	1
Vincristine	decreases expression	1
Sertraline	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3KK	Abcam HEK293T UBE2G1 KO	Transformed cell line	Female
CVCL_TV68	HAP1 UBE2G1 (-) 1	Cancer cell line	Male
CVCL_TV69	HAP1 UBE2G1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.